Precigen Inc (PGEN) Stock Price, Quote & News

Company Profile

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine an...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 556 9900

Website: precigen.com

Address:

20374 Seneca Meadows Parkway, Germantown, United States

InstinctiveLGoons Aug. 30 at 2:13 AM

$PGEN this sentiment is so artifical should be 80+.

0 · Reply

ManUtd303 Aug. 29 at 10:06 PM

$PGEN Insider buy is great but also means nothing material like a Partnership or BO was happening.

2 · Reply

Wacousta Aug. 29 at 8:48 PM

$PGEN FYI https://investors.precigen.com/node/14451/html

3 · Reply

InstinctiveLGoons Aug. 29 at 8:37 PM

$PGEN afterhours... somethings brewing...

0 · Reply

WallStJesus Aug. 29 at 8:26 PM

$PGEN INSIDER BUY

1 · Reply

EMoons52 Aug. 29 at 8:01 PM

$PGEN watch the sell off, might have to buy back at a higher price !

0 · Reply

Bordeaux17 Aug. 29 at 7:21 PM

$PGEN Don’t sweat it —Healthy pullback. Above $4.26 = strong. Break $4.83 and the next leg higher starts. Bigger picture still $5–8. She’s sitting pretty !!!!

0 · Reply

erkdg Aug. 29 at 7:10 PM

$PGEN are they going to have an other webinar on tuesday? I remember seeing it but cant find now.

1 · Reply

mimiwor Aug. 29 at 7:02 PM

$PGEN this Fking MM F U

1 · Reply

Slipvayne99 Aug. 29 at 6:56 PM

$PGEN adding soon

0 · Reply

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

Aug 22, 2025, 10:43 AM EDT - 8 days ago

Undercovered Dozen: Precigen, ONEOK, Bitmine And More

BMNR OKE

Aug 15, 2025, 3:15 PM EDT - 15 days ago

Precigen: This Billion-Dollar Approval Is Still Undervalued

Aug 15, 2025, 9:48 AM EDT - 15 days ago

Why Is Precigen Stock Surging On Friday?

Aug 15, 2025, 7:18 AM EDT - 15 days ago

US FDA approves Precigen's immunotherapy for rare respiratory disease

Aug 15, 2025, 7:00 AM EDT - 15 days ago

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Jul 7, 2025, 5:58 PM EDT - 7 weeks ago

Precigen: August Is Pivotal For This Biotech Innovator

May 14, 2025, 4:05 PM EDT - 3 months ago

Precigen Reports First Quarter 2025 Financial Results and Business Updates

Apr 16, 2025, 8:05 AM EDT - 4 months ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

Mar 19, 2025, 7:47 PM EDT - 5 months ago

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 4:05 PM EDT - 5 months ago

Precigen Reports Full Year 2024 Financial Results and Business Updates

Mar 13, 2025, 8:05 AM EDT - 6 months ago

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

Feb 28, 2025, 8:56 AM EST - 6 months ago

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

Feb 25, 2025, 8:05 AM EST - 6 months ago

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Jan 13, 2025, 7:00 AM EST - 8 months ago

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:30 AM EST - 8 months ago

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 30, 2024, 7:00 AM EST - 8 months ago

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Dec 27, 2024, 9:00 AM EST - 8 months ago

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Nov 14, 2024, 4:30 PM EST - 10 months ago

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Nov 12, 2024, 4:05 PM EST - 10 months ago

Precigen to Participate in the Stifel 2024 Healthcare Conference

Sep 16, 2024, 4:30 PM EDT - 1 year ago

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Aug 15, 2024, 8:11 AM EDT - 1 year ago

Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session

GGR TITN

Aug 14, 2024, 7:03 PM EDT - 1 year ago

Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Aug 7, 2024, 9:30 PM EDT - 1 year ago

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Aug 6, 2024, 4:04 PM EDT - 1 year ago

Precigen Announces Proposed $30 Million Public Offering of Common Stock

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

Jul 23, 2024, 8:01 AM EDT - 1 year ago

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

Jun 3, 2024, 9:30 AM EDT - 1 year ago

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

May 23, 2024, 5:00 PM EDT - 1 year ago

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

May 14, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports First Quarter 2024 Financial Results and Business Updates

May 8, 2024, 4:05 PM EDT - 1 year ago

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

Apr 24, 2024, 10:20 AM EDT - 1 year ago

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Apr 24, 2024, 9:00 AM EDT - 1 year ago

Actym Therapeutics Appoints Thomas Smart as CEO

ANAB XOMA

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

Mar 19, 2024, 8:49 PM EDT - 1 year ago

Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports Full Year 2023 Financial Results and Business Updates

Mar 12, 2024, 4:05 PM EDT - 1 year ago

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Mar 5, 2024, 4:05 PM EST - 1 year ago

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

Feb 6, 2024, 4:05 PM EST - 1 year ago

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 19, 2024, 7:39 PM EST - 1 year ago

Precigen: RRP Targeting With AdenoVerse Technology Platform

Jan 16, 2024, 8:05 AM EST - 1 year ago

Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Jan 8, 2024, 8:30 AM EST - 1 year ago

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 18, 2023, 4:05 PM EST - 1 year ago

Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 29, 2023, 4:05 PM EST - 1 year ago

Precigen to Participate in the JMP Securities Hematology and Oncology Summit

Nov 9, 2023, 4:55 PM EST - 1 year ago

Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs

Nov 7, 2023, 4:05 PM EST - 1 year ago

Precigen to Participate in the Stifel 2023 Healthcare Conference

Sep 19, 2023, 4:05 PM EDT - 2 years ago

Precigen to Participate in Upcoming Leading Investor and Industry Conferences

Aug 28, 2023, 9:15 AM EDT - 2 years ago

Precigen's Express Lane: Racing Towards RRP Remedies (Rating Upgrade)

InstinctiveLGoons Aug. 30 at 2:13 AM

$PGEN this sentiment is so artifical should be 80+.

0 · Reply

ManUtd303 Aug. 29 at 10:06 PM

$PGEN Insider buy is great but also means nothing material like a Partnership or BO was happening.

2 · Reply

Wacousta Aug. 29 at 8:48 PM

$PGEN FYI https://investors.precigen.com/node/14451/html

3 · Reply

InstinctiveLGoons Aug. 29 at 8:37 PM

$PGEN afterhours... somethings brewing...

0 · Reply

WallStJesus Aug. 29 at 8:26 PM

$PGEN INSIDER BUY

1 · Reply

EMoons52 Aug. 29 at 8:01 PM

$PGEN watch the sell off, might have to buy back at a higher price !

0 · Reply

Bordeaux17 Aug. 29 at 7:21 PM

$PGEN Don’t sweat it —Healthy pullback. Above $4.26 = strong. Break $4.83 and the next leg higher starts. Bigger picture still $5–8. She’s sitting pretty !!!!

0 · Reply

erkdg Aug. 29 at 7:10 PM

$PGEN are they going to have an other webinar on tuesday? I remember seeing it but cant find now.

1 · Reply

mimiwor Aug. 29 at 7:02 PM

$PGEN this Fking MM F U

1 · Reply

Slipvayne99 Aug. 29 at 6:56 PM

$PGEN adding soon

0 · Reply

Avoc Aug. 29 at 6:53 PM

$PGEN Exited at 4.45. Don't like long weekends. Might rejoin with a smaller position next week. Otherwise, good luck longs!

0 · Reply

wallstbullinfinity Aug. 29 at 6:17 PM

$PGEN and the fact buddy elaborating on the lie is pretty disturbing. Apparently, he knows where everyone lives who post on this app... which sounds pretty sketchy to even want that ability lol besides, Bentley doesn't even work for Inovio lol. The reason you'll never be able to prove it because it's a lie lol You guys need to stop making stuff up so much. It's not mentally healthy.

1 · Reply

Bio_Invest101 Aug. 29 at 4:58 PM

$PGEN My thought on funding issue since FDA approval. Nothing to be shocked and admitting freely that we need funding for future drug sales to generate revenue and to develop pipelines.” Borrowing money to make more money” The management stressed again that they don’t need cash desperately since the money saved from NOT having to do the costly confirmatory ph3 by the FULL FDA approval of PAPZIMEOS bought some time. This is fact not opinion. As for the source of funding, the CEO clearly stated on record that they won’t do stock dilutions. So I believe strongly that they’re working on royalty deals for non diluted funding deals with some industrial leaders in biotech royalty business. Read links below and think during the long weekend. Patience is much needed and time is on our long side. Just IMO and do your own DD. There’s really not much to talk about for now. Enjoy your long holiday weekend!!

0 · Reply

InstinctiveLGoons Aug. 29 at 4:28 PM

$PGEN finding much better support... looks like she wants to move in only one direction😝😤

1 · Reply

Bio_Invest101 Aug. 29 at 4:03 PM

$PGEN IWM - iShares Russell 2000 ETF reports 3.36% increase in ownership of PGEN / Precigen, Inc. On August 28, 2025 - IWO - iShares Russell 2000 Growth ETF filed a NPORT-P form disclosing ownership of 1,212,517 shares of Precigen, Inc. (US:PGEN) valued at $1,721,774 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 27, 2025 disclosing 98,492 shares of Precigen, Inc.. This represents a change in shares of 1,131.08% during the quarter. On August 28, 2025 - IWM - iShares Russell 2000 ETF filed a NPORT-P form disclosing ownership of 3,722,681 shares of Precigen, Inc. (US:PGEN) valued at $5,286,207 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 27, 2025 disclosing 3,601,580 shares of Precigen, Inc.. This represents a change in shares of 3.36% during the quarter.

1 · Reply

blue_horseshoe_9P Aug. 29 at 3:56 PM

$PGEN $4.83 was yesterday’s intraday high…let’s blast through that to $5!!

0 · Reply

JFDI Aug. 29 at 3:51 PM

$PGNY or $PGEN

1 · Reply

Kpax4OSU Aug. 29 at 3:50 PM

$PGEN powering through a sea of red today!

0 · Reply

ripztrip Aug. 29 at 3:10 PM

$CAPR To give you a slight glimpse here of where we can also be shortly with FDA progress & positive HOPE 3 endpoints! $SRPT $REPL $PGEN

1 · Reply

SouthSideInvest Aug. 29 at 2:59 PM

$PGEN biggest regret is I sold at $2.67

1 · Reply

updownsides Aug. 29 at 2:43 PM

$PGEN Salzgitter, Germany – construction began in July 2022 (VW called it the “groundbreaking of the first PowerCo cell factory”). Production is scheduled to ramp in 2025 with ~40 GWh annual capacity in its first phase. Valencia, Spain – groundbreaking was held in March 2023. Production is planned for 2026 (~40 GWh). St. Thomas, Canada – announced in 2023, with construction beginning in 2024. Production target is 2027, scaling to 90 GWh at full build-out. 170GWh total capable of going to 200GWh if demanding. What's half of 170GWh? The same as the PowerCo deal, 85GWh. Are they planning on 50% capacity for QS?

0 · Reply

Bio_Invest101 Aug. 29 at 2:35 PM

$PGEN over 2 million shares in 1st hour and one of few green spots in biotech rn. It must have driven some people nuts. IMO Big or small partnership deals are in the work for sure. Enjoy your weekend Longs!!

1 · Reply

Market Cap	1.37B
Revenue (ttm)	3.93M
Net Income (ttm)	-126.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,212.21%
Debt to Equity Ratio	0.00

Volume	9,114,100
Avg Vol	8,574,836
Day's Range	N/A - N/A
Shares Out	297.97M
Stochastic %K	83%
Beta	1.87
Analysts	Strong Sell
Price Target	$8.25